Matias Arrupe: The Value of Lipoprotein(a) in Reclassifying Cardiovascular Risk
Matias Arrupe, Cardiologist at CardioInnova Medical Research, shared on LinkedIn:
”Reclassifying Cardiovascular Risk with a Simple Test: The Value of Lipoprotein(a)
New insights from a pilot study in Spain highlight how Lipoprotein(a) (Lp(a)) can uncover hidden cardiovascular risk even in patients classified as low or moderate risk.
Study Overview:
Participants: 140 adults (62.9% women, average age 54.3)
Initial Classification: Low (41.4%) or Moderate (58.6%) cardiovascular risk (SCORE2)
Intervention: Lp(a) measurement
Outcome: Reclassification based on Lp(a) >50 mg/dL
Key Findings:
- 22.1% had Lp(a) >50 mg/dL
- 22.6% of low-risk individuals were reclassified to moderate risk
- 77.4% of moderate-risk individuals were reclassified to high risk
- 61.4% of the cohort became eligible for statin therapy
Why Lp(a) Matters:
- Lp(a) levels are genetically determined in over 80% of individuals.
- One single measurement is sufficient to assess lifetime cardiovascular risk.
- Elevated levels are not affected by age or lifestyle.
- Lp(a) >180 mg/dL may confer a risk similar to familial hypercholesterolemia.
Clinical Implications:
- Most individuals with elevated Lp(a) would otherwise remain undiagnosed.
- Measuring Lp(a) could shift therapeutic decisions significantly.
- Potential for family screening due to hereditary nature.
Challenges and Future Steps:
- Lp(a) is rarely measured despite guidelines recommending at least one lifetime assessment.
- No targeted therapies to lower Lp(a) below 50 mg/dL, but PCSK9 inhibitors show promise.
- This pilot study may lead to routine inclusion of Lp(a) in cardiovascular screening protocols.
This research reinforces the necessity of moving toward personalized risk assessment in cardiovascular care.”
Title: Reclassification of Low or Intermediate Cardiovascular Risk by Determining Lipoprotein(a) Levels
Authors: Alberto Cordero, José Ma Salinas, María Amparo Quintanilla, José Ma López-Ayala, Álvaro Blasco, Emilio Flores
Read the full article here.
Stay informed with Hemostasis Today.
-
Oct 30, 2026, 13:42Wolfgang Miesbach: Gene Therapy-Associated Leukaemia With Clonal Persistence Over 16 Years
-
Oct 30, 2026, 12:47Louise St. Germain Bannon: Turning Thrombosis Awareness into Stroke Prevention
-
Oct 30, 2026, 12:36Aryabhatta Sadhu: Sickle Cell Crisis Recognising When Treatment Must Change
-
Oct 30, 2026, 12:22Fabrice Cognasse: The Future of Blood Banks From Transfusion Support to Precision Medicine
-
Oct 30, 2026, 12:09Carmelo Gurnari: Clonal Dynamics in the Bone Marrow During Sepsis and Emergency Haematopoiesis
-
Oct 30, 2026, 11:49Advancing Global Care for Hemophilia and Bleeding Disorders – World Federation of Hemophilia
-
Oct 30, 2026, 05:18Flora Peyvandi: Molecular and Lab Markers Linked to Bleeding Severity in Factor VII Deficiency
-
Oct 30, 2026, 05:11Rana Al-Hrout: Exploring Approach to Macrocytic Anemia
-
Oct 30, 2026, 04:22Francisco Chacón-Lozsán: Acute Pulmonary Embolism in 2026 – Blood Pressure Is Not the Same as Perfusion